Clinical News

PharmaTwitter

Follow me on Twitter

Alcon in hand, Novartis zeroes in on minority stak...
Novartis is moving full speed ahead in its bid to buy out Alcon s minority shareholders--in spite of the eye care c
Alcon minorities may get higher Novartis bid
Novartis (NYSE:NVS) doesn t just have to worry about Alcon s (NYSE:ACL) balky independent directors as it work
Strong Q2 prompts new call for higher Alcon bid
Alcon s independent directors must be grinning, now that the company has posted street-beating second-quarter earnings.
Novartis chief stands firm on Alcon bid
Novartis isn t budging in its fight to buy 100 percent of Alcon s shares. This, after some public saber-rattling on
Alcon IDC earmarks $50M for possible Novartis suit
Alcon s (NYSE: ACL) independent directors are upping the ante in their squabble with Novartis. The directors committee (
Novartis faces new obstacle in Alcon deal
Novartis may come to regret its lower-than-expected offer to Alcon s (NYSE: ACL) minority shareholders. A legal expert h

Share it on Facebook!

Categories

Compliance/Regulatory

News & More

National Health News

World Health News

Company-Specific News

Physician Perspectives

Professional Perspectives

Compliance/Regulatory News

Drug-Specific News

News by Specialty

Legislative News

Marketing Trends News

Medical Device News

Inside Pharma

Company Profiles

Mergers & Acquisitions

Training & Education

Conference Updates

Speaker Directory

Back

PharmaLeaders

Solutions

Call for Speakers

Tools & Resources

My Daily Update

Features

Company Profiles

Physician Perspectives

Professional Perspectives

Content Partners

President: Jim Miller, jmiller@pharmaleaders.com

Editorial Director: Robin Jay, rjay@pharmaleaders.com
Technical Support: Charles Ob'Brien, cpobrien@nsminc.com

Follow us on Twitter

twitter.com/jamesjmiller for President Jim Miller's insight into pharma news, PR initiatives and social media
twitter.com/jamesjmiller/pharma for pharma news

Copyright Collaborative Marketing Solutions © 2010